Alvotech (ALVOW) Stock Price, News & Analysis

Company Overview

Alvotech is a biopharmaceutical company headquartered in Reykjavik, Iceland, focused on developing and manufacturing biosimilar medicines. Biosimilars are biological products designed to be highly similar to already approved biologic therapies and are intended to expand patient access to complex treatments at potentially lower costs.

The company operates an integrated platform covering cell-line development, process development, analytical testing, clinical development and commercial-scale manufacturing. Its pipeline has included biosimilar candidates in areas such as immunology, ophthalmology, oncology and autoimmune disease, including products targeting therapies with applications in conditions such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.

Alvotech serves international markets through commercial and strategic partnerships with pharmaceutical companies and distributors. Its products and candidates have been developed for markets including the United States, Europe and other regions, with regulatory approvals and commercial availability varying by product and geography. The company was founded in 2013 by Robert Wessman, who has been associated with Alvotech’s leadership as executive chairman.

Key Stats

• Today's Range: $0.26 to $0.26
• 50-Day Range: $0.15 to $0.49
• 52-Week Range: $0.12 to $3.00
• Volume: 100 shs
• Average Volume: 4,444 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/03/2026
• Next Earnings (Estimated): 11/11/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALVOW
• CIK: 1898416
• Web: www.alvotech.com
• Phone: 354 422 4500
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $491.95 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A